USFDA gives nod to Glenmark for Nasal Spray to treat allergic rhinitis

The product is used for the treatment of symptoms of seasonal allergic rhinitis

56
USFDA
Picture: Pixabay

Last Updated on January 16, 2022 by The Health Master

Glenmark Pharmaceuticals today said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.

The company’s fully-owned unit Glenmark Specialty SA (Switzerland) has received approval from the USFDA for its New Drug Application (NDA) for Ryaltris, a fixed-dose (metered), prescription, combination nasal spray, Glenmark Pharmaceuticals said in a statement.

The product is used for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older, it added.

“The USFDA’s approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas,” said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals.

With this NDA approval, the company looks forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms, he added.

Ryaltris will be marketed and distributed in the United States by Hikma Specialty USA, Inc, as part of its exclusive licensing agreement with Glenmark Specialty SA.

Ryaltris has been approved and is marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, the UK and Uzbekistan.

Glenmark concluded the regulatory procedure in Europe, enabling approval in 17 countries across the EU and the UK.

The drug firm has entered into commercial agreements with several partners around the world, including Menarini for the commercialization of the drug in select EU markets and with Bausch Health in Canada.

USFDA gives tentative nod to Alembic for Dronedarone tablets

USFDA gives nod to Alembic Pharma for Vortioxetine tablets

USFDA gives nod to Alembic for generic drug to treat Parkinson’s disease

USFDA gives nod to Alembic Pharma for Doxycycline Hyclate tablets

USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules

USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection

Narcotic Control Bureau seizes Drugs worth Rs 30 lakh

Big Pharma Companies buying land in Hyderabad

Govt warns against overuse, misuse of COVID medicines

BIS notifies new standard for these Medical Devices

Licensing procedure for Medical devices

Latest Notifications: Medical Devices

Classifications of Medical Devices under the provisions of MDR 2017

FAQs on Medical Devices Rules, 2017   

FAQs – on Blood Pressure Monitoring DevicesAlso read

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner